About ACGN
Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm's product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Durham, NC.